XML 124 R95.htm IDEA: XBRL DOCUMENT
v3.24.1

Other Non-Financial Assets - Additional Information (Details) - EUR (€) € in Millions | Dec. 31, 2023 | Dec. 31, 2022
--- | --- | ---
Disclosure Of Income And Expenses [Line Items] |  |
Deferred expenses | € 313.2 | € 120.0
OncoC4 Inc. |  |
Disclosure Of Income And Expenses [Line Items] |  |
Deferred expenses | 22.5 | 0.0
Ryvu Therapeutics S.A. |  |
Disclosure Of Income And Expenses [Line Items] |  |
Deferred expenses | 15.7 | 19.7
Medigene Immunotherapies GmbH |  |
Disclosure Of Income And Expenses [Line Items] |  |
Deferred expenses | 5.1 | 9.4
European Commission To Collaboration Partner |  |
Disclosure Of Income And Expenses [Line Items] |  |
Deferred expenses | € 151.1 | € 0.0

X
- Definition Deferred Expense + References No definition available. + Details
Name: | bntx_DeferredExpense
Namespace Prefix: | bntx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disclosure Of Income And Expenses + References No definition available. + Details
Name: | bntx_DisclosureOfIncomeAndExpensesLineItems
Namespace Prefix: | bntx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_OncoC4IncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_RyvuTherapeuticsSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_MedigeneImmunotherapiesGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=bntx_EuropeanCommissionToCollaborationPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |